



Clinical trial results:

A randomized, subject and investigator blinded, placebo-controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Summary

| | |
|--------------------------|-------------------------|
| EudraCT number | 2018-002757-30 |
| Trial protocol | FR HU DK NL IS CZ BE ES |
| Global end of trial date | |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 11 December 2025 |
| First version publication date | 11 December 2025 |

Trial information

Trial identification

| | |
|-----------------------|-----------------|
| Sponsor protocol code | CCFZ533H12201BC |
|-----------------------|-----------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03827798 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Novartis Pharma AG |
| Sponsor organisation address | Lichtstrasse 35, Basel, Switzerland, 4056 |
| Public contact | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com |
| Scientific contact | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Interim |
| Date of interim/final analysis | 04 December 2024 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 04 December 2024 |
| Global end of trial reached? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to assess the efficacy of the investigational treatments compared to the pooled placebo group from Cohorts A, B, C, and D, in moderate to severe inflammatory hidradenitis suppurativa (HS) patients by comparing the proportion of participants achieving clinical response defined by the simplified Hidradenitis Suppurativa Clinical Response (sHiSCR) after 16 weeks of treatment. This study has a cohort E which is ongoing and will be reported in CTIS.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 27 February 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Austria: 3 |
| Country: Number of subjects enrolled | Belgium: 13 |
| Country: Number of subjects enrolled | Czechia: 12 |
| Country: Number of subjects enrolled | Denmark: 5 |
| Country: Number of subjects enrolled | France: 50 |
| Country: Number of subjects enrolled | Germany: 28 |
| Country: Number of subjects enrolled | Hungary: 19 |
| Country: Number of subjects enrolled | Iceland: 1 |
| Country: Number of subjects enrolled | Netherlands: 14 |
| Country: Number of subjects enrolled | Spain: 29 |
| Country: Number of subjects enrolled | United States: 31 |
| Worldwide total number of subjects | 205 |
| EEA total number of subjects | 174 |

Notes:

Subjects enrolled per age group

| | |
|----------|---|
| In utero | 0 |
|----------|---|

| | |
|---|-----|
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 205 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants took part in 36 investigative sites in 11 countries.

Pre-assignment

Screening details:

The study consisted of a screening period of up to 35 days.

Period 1

| | |
|------------------------------|--|
| Period 1 title | Treatment Epoch (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Carer, Assessor, Subject |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|--------------------------|
| Arm title | Cohort A - CFZ533 600 mg |
|------------------|--------------------------|

Arm description:

CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | CFZ533 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

| | |
|------------------|------------------------------|
| Arm title | Cohort A - Placebo to CFZ533 |
|------------------|------------------------------|

Arm description:

Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

| | |
|------------------|-------------------------|
| Arm title | Cohort B - LYS006 20 mg |
|------------------|-------------------------|

Arm description:

LYS006 20 mg administered orally twice per day until Week 16.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|---|------------------------------|
| Investigational medicinal product name | LYS006 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |
| Dosage and administration details: LYS006 20 mg administered orally twice per day until Week 16. | |
| Arm title | Cohort B - Placebo to LYS006 |
| Arm description: Placebo administered orally twice per day until Week 16. | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |
| Dosage and administration details: Placebo administered orally twice per day until Week 16. | |
| Arm title | Cohort C - MAS825 300 mg |
| Arm description: MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. | |
| Arm type | Experimental |
| Investigational medicinal product name | MAS825 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. | |
| Arm title | Cohort C - Placebo to MAS825 |
| Arm description: Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. | |
| Arm title | Cohort D - LOU064 25 mg |
| Arm description: LOU064 25 mg administered orally twice per day until Week 16. | |
| Arm type | Experimental |
| Investigational medicinal product name | LOU064 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

LOU064 25 mg administered orally twice per day until Week 16.

| | |
|--|--------------------------|
| Arm title | Cohort D - LOU064 100 mg |
| Arm description: LOU064 100 mg administered orally twice per day until Week 16. | |
| Arm type | Experimental |
| Investigational medicinal product name | LOU064 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

LOU064 100 mg administered orally twice per day until Week 16.

| | |
|--|------------------------------|
| Arm title | Cohort D - Placebo to LOU064 |
| Arm description: Placebo administered orally twice per day until Week 16. | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo administered orally twice per day until Week 16.

| Number of subjects in period 1 | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg |
|---------------------------------------|-----------------------------|---------------------------------|----------------------------|
| Started | 29 | 16 | 27 |
| Completed | 25 | 12 | 20 |
| Not completed | 4 | 4 | 7 |
| Consent withdrawn by subject | 2 | 3 | 4 |
| Physician decision | 1 | - | 1 |
| Protocol Deviation | - | - | 1 |
| Adverse event | 1 | 1 | 1 |
| Lost to follow-up | - | - | - |

| Number of subjects in period 1 | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 |
|---------------------------------------|---------------------------------|-----------------------------|---------------------------------|
| Started | 13 | 33 | 10 |
| Completed | 9 | 29 | 9 |
| Not completed | 4 | 4 | 1 |
| Consent withdrawn by subject | 1 | 2 | 1 |
| Physician decision | 2 | 1 | - |

| | | | |
|--------------------|---|---|---|
| Protocol Deviation | - | - | - |
| Adverse event | 1 | 1 | - |
| Lost to follow-up | - | - | - |

| Number of subjects in period 1 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 |
|---------------------------------------|----------------------------|-----------------------------|---------------------------------|
| Started | 33 | 33 | 11 |
| Completed | 29 | 26 | 8 |
| Not completed | 4 | 7 | 3 |
| Consent withdrawn by subject | 4 | 3 | 2 |
| Physician decision | - | - | - |
| Protocol Deviation | - | - | - |
| Adverse event | - | 3 | - |
| Lost to follow-up | - | 1 | 1 |

Baseline characteristics

| Reporting groups | |
|------------------------------|--|
| Reporting group title | Cohort A - CFZ533 600 mg |
| Reporting group description: | CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15. |
| Reporting group title | Cohort A - Placebo to CFZ533 |
| Reporting group description: | Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15. |
| Reporting group title | Cohort B - LYS006 20 mg |
| Reporting group description: | LYS006 20 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort B - Placebo to LYS006 |
| Reporting group description: | Placebo administered orally twice per day until Week 16. |
| Reporting group title | Cohort C - MAS825 300 mg |
| Reporting group description: | MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. |
| Reporting group title | Cohort C - Placebo to MAS825 |
| Reporting group description: | Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. |
| Reporting group title | Cohort D - LOU064 25 mg |
| Reporting group description: | LOU064 25 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort D - LOU064 100 mg |
| Reporting group description: | LOU064 100 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort D - Placebo to LOU064 |
| Reporting group description: | Placebo administered orally twice per day until Week 16. |

| Reporting group values | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg |
|--|--------------------------|------------------------------|-------------------------|
| Number of subjects | 29 | 16 | 27 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 29 | 16 | 27 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Age Continuous Units: years arithmetic mean standard deviation | 38.0 ± 8.68 | 41.4 ± 9.54 | 36.4 ± 9.62 |
| Sex: Female, Male Units: participants | | | |
| Female | 16 | 10 | 17 |
| Male | 13 | 6 | 10 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian | 1 | 0 | 1 |
| Black Or African American | 1 | 1 | 1 |
| Other | 1 | 0 | 1 |
| Unknown | 0 | 0 | 0 |
| White | 26 | 15 | 24 |

| Reporting group values | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 |
|---|---------------------------------|-----------------------------|---------------------------------|
| Number of subjects | 13 | 33 | 10 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 13 | 33 | 10 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: years arithmetic mean standard deviation | 36.5 ± 13.29 | 39.5 ± 8.22 | 36.9 ± 10.26 |
| Sex: Female, Male Units: participants | | | |
| Female | 7 | 19 | 3 |
| Male | 6 | 14 | 7 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian | 0 | 0 | 0 |
| Black Or African American | 0 | 1 | 0 |
| Other | 0 | 5 | 0 |
| Unknown | 0 | 1 | 0 |
| White | 13 | 26 | 10 |

| Reporting group values | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 |
|-------------------------------|----------------------------|-----------------------------|---------------------------------|
| Number of subjects | 33 | 33 | 11 |

| | | | |
|---|---------|---------|--------|
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 33 | 33 | 11 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: years | | | |
| arithmetic mean | 35.6 | 35.3 | 44.1 |
| standard deviation | ± 10.84 | ± 10.99 | ± 7.83 |
| Sex: Female, Male Units: participants | | | |
| Female | 18 | 20 | 3 |
| Male | 15 | 13 | 8 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| Asian | 0 | 1 | 0 |
| Black Or African American | 1 | 1 | 1 |
| Other | 2 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
| White | 30 | 31 | 10 |

| | | | |
|---|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 205 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 205 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age Continuous Units: years | | | |
| arithmetic mean | - | | |
| standard deviation | - | | |
| Sex: Female, Male Units: participants | | | |
| Female | 113 | | |
| Male | 92 | | |

| Race/Ethnicity, Customized | | | |
|----------------------------|-----|--|--|
| Units: Subjects | | | |
| Asian | 3 | | |
| Black Or African American | 7 | | |
| Other | 9 | | |
| Unknown | 1 | | |
| White | 185 | | |

End points

End points reporting groups

| | |
|-----------------------------------|--|
| Reporting group title | Cohort A - CFZ533 600 mg |
| Reporting group description: | CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15. |
| Reporting group title | Cohort A - Placebo to CFZ533 |
| Reporting group description: | Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15. |
| Reporting group title | Cohort B - LYS006 20 mg |
| Reporting group description: | LYS006 20 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort B - Placebo to LYS006 |
| Reporting group description: | Placebo administered orally twice per day until Week 16. |
| Reporting group title | Cohort C - MAS825 300 mg |
| Reporting group description: | MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. |
| Reporting group title | Cohort C - Placebo to MAS825 |
| Reporting group description: | Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13. |
| Reporting group title | Cohort D - LOU064 25 mg |
| Reporting group description: | LOU064 25 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort D - LOU064 100 mg |
| Reporting group description: | LOU064 100 mg administered orally twice per day until Week 16. |
| Reporting group title | Cohort D - Placebo to LOU064 |
| Reporting group description: | Placebo administered orally twice per day until Week 16. |
| Subject analysis set title | Pooled Placebo (Cohorts A, B and C) |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | Placebo to CFZ533, LYS006 and MAS825. |
| Subject analysis set title | Pooled Placebo (Cohorts A, B, C and D) |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | Placebo to CFZ533, LYS006, MAS825 and LOU064. |

Primary: Percentage of participants achieving Clinical Response measured by simplified Hidradenitis Suppurativa (sHiSCR)

| | |
|------------------------|---|
| End point title | Percentage of participants achieving Clinical Response measured by simplified Hidradenitis Suppurativa (sHiSCR) ^[1] |
| End point description: | sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and pooled placebo groups were computed respectively. At the time of the statistical comparison for cohorts A, B, and C, the placebo data for cohorts D and E were incomplete and therefore excluded. Similarly, during the comparison for cohort D, the placebo data for cohort E was still pending and was not included. |

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline, Week 16

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is specific for the arms presented.

| End point values | Cohort A - CFZ533 600 mg | Cohort B - LYS006 20 mg | Cohort C - MAS825 300 mg | Cohort D - LOU064 25 mg |
|-----------------------------------|--------------------------|-------------------------|--------------------------|-------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 29 | 25 | 32 | 33 |
| Units: percentage of participants | | | | |
| number (not applicable) | 58.62 | 32.00 | 46.88 | 72.73 |

| End point values | Cohort D - LOU064 100 mg | Pooled Placebo (Cohorts A, B and C) | Pooled Placebo (Cohorts A, B, C and D) | |
|-----------------------------------|--------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 33 | 39 | 49 | |
| Units: percentage of participants | | | | |
| number (not applicable) | 48.48 | 35.9 | 34.69 | |

Statistical analyses

| Statistical analysis title | Clinical Response |
|---|--|
| Comparison groups | Cohort A - CFZ533 600 mg v Pooled Placebo (Cohorts A, B and C) |
| Number of subjects included in analysis | 68 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Posterior estimate treatment difference |
| Point estimate | 22.1 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 2.5 |
| upper limit | 41 |

| Statistical analysis title | Clinical Response |
|----------------------------|---|
| Comparison groups | Cohort B - LYS006 20 mg v Pooled Placebo (Cohorts A, B and C) |

| | |
|---|---|
| Number of subjects included in analysis | 64 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Posterior estimate treatment difference |
| Point estimate | -3.3 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -21.9 |
| upper limit | 15.9 |

| | |
|---|--|
| Statistical analysis title | Clinical Response |
| Comparison groups | Cohort C - MAS825 300 mg v Pooled Placebo (Cohorts A, B and C) |
| Number of subjects included in analysis | 71 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Posterior estimate treatment difference |
| Point estimate | 12.2 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.5 |
| upper limit | 31.6 |

| | |
|---|--|
| Statistical analysis title | Clinical Response |
| Comparison groups | Cohort D - LOU064 25 mg v Pooled Placebo (Cohorts A, B, C and D) |
| Number of subjects included in analysis | 82 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Posterior estimate treatment difference |
| Point estimate | 37.2 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 19.7 |
| upper limit | 53 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Clinical Response |
| Comparison groups | Cohort D - LOU064 100 mg v Pooled Placebo (Cohorts A, B, C and D) |

| | |
|---|---|
| Number of subjects included in analysis | 82 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Posterior estimate treatment difference |
| Point estimate | 13.9 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -4.2 |
| upper limit | 31.9 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Cohorts A, B and C: 28 weeks including 12 weeks follow up period.

Cohort D: 20 weeks including 4 weeks follow up period.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 27.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort A-CFZ533 600 mg |
|-----------------------|------------------------|

Reporting group description:

CFZ533 600 mg

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort C-MAS825 300 mg |
|-----------------------|------------------------|

Reporting group description:

MAS825 300 mg

| | |
|-----------------------|-----------------------|
| Reporting group title | Cohort B-LYS006 20 mg |
|-----------------------|-----------------------|

Reporting group description:

LYS006 20 mg

| | |
|-----------------------|-----------------------|
| Reporting group title | Cohort D-LOU064 25 mg |
|-----------------------|-----------------------|

Reporting group description:

LOU064 25 mg

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort D-LOU064 100 mg |
|-----------------------|------------------------|

Reporting group description:

LOU064 100 mg

| | |
|-----------------------|----------------|
| Reporting group title | Pooled Placebo |
|-----------------------|----------------|

Reporting group description:

Pooled Placebo (Cohorts A, B, C and D)

| | |
|-----------------------|-------|
| Reporting group title | Total |
|-----------------------|-------|

Reporting group description:

Total

| Serious adverse events | Cohort A-CFZ533 600 mg | Cohort C-MAS825 300 mg | Cohort B-LYS006 20 mg |
|---|---------------------------|---------------------------|--------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 29 (13.79%) | 1 / 33 (3.03%) | 2 / 27 (7.41%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 1 / 27 (3.70%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|----------------|
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular torsion | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Alcohol withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 1 / 27 (3.70%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 1 / 33 (3.03%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Genital abscess | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 29 (3.45%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular abscess | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Cohort D-LOU064 25 mg | Cohort D-LOU064 100 mg | Pooled Placebo |
|--|-----------------------|------------------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 33 (3.03%) | 1 / 33 (3.03%) | 1 / 50 (2.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 1 / 33 (3.03%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 33 (3.03%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular torsion | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Alcohol withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Genital abscess | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular abscess | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 1 / 50 (2.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Total | | |
|--|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 10 / 205 (4.88%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Testicular torsion | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Alcohol withdrawal syndrome | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Depression | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Abscess limb | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Genital abscess | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Testicular abscess | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Cohort A-CFZ533 600 mg | Cohort C-MAS825 300 mg | Cohort B-LYS006 20 mg |
|--|---------------------------|---------------------------|--------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 23 / 29 (79.31%) | 22 / 33 (66.67%) | 19 / 27 (70.37%) |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bacterial test positive | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | 1 / 33 (3.03%) | 1 / 27 (3.70%) |
| occurrences (all) | 2 | 1 | 1 |
| Blood glucose increased | | | |
| subjects affected / exposed | 0 / 29 (0.00%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | 1 / 33 (3.03%) | 0 / 27 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Nitrite urine present | | | |
| subjects affected / exposed | 2 / 29 (6.90%) | 0 / 33 (0.00%) | 0 / 27 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Crystal urine present | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 1 / 27 (3.70%) 1 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 2 / 33 (6.06%) 2 | 0 / 27 (0.00%) 0 |
| Urine albumin/creatinine ratio increased subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 3 | 1 / 33 (3.03%) 2 | 3 / 27 (11.11%) 3 |
| Vascular disorders Hypertension subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 1 / 33 (3.03%) 1 | 1 / 27 (3.70%) 1 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 4 | 5 / 33 (15.15%) 7 | 4 / 27 (14.81%) 4 |
| Dizziness subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 33 (0.00%) 0 | 2 / 27 (7.41%) 3 |
| General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 3 / 33 (9.09%) 3 | 4 / 27 (14.81%) 4 |
| Asthenia subjects affected / exposed occurrences (all) | 3 / 29 (10.34%) 3 | 2 / 33 (6.06%) 2 | 0 / 27 (0.00%) 0 |
| Pyrexia subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 1 / 33 (3.03%) 2 | 3 / 27 (11.11%) 3 |
| Blood and lymphatic system disorders Increased tendency to bruise subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Gastrointestinal disorders Diarrhoea | | | |

| | | | |
|---|---------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 2 / 33 (6.06%) 2 | 1 / 27 (3.70%) 1 |
| Constipation subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 33 (0.00%) 0 | 1 / 27 (3.70%) 1 |
| Flatulence subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 2 / 27 (7.41%) 2 |
| Abdominal pain subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 1 / 33 (3.03%) 1 | 2 / 27 (7.41%) 2 |
| Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Pain of skin subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Hidradenitis subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 5 / 33 (15.15%) 6 | 2 / 27 (7.41%) 3 |
| Erythema subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 1 / 33 (3.03%) 1 | 0 / 27 (0.00%) 0 |
| Renal and urinary disorders Proteinuria subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 33 (0.00%) 0 | 1 / 27 (3.70%) 1 |
| Psychiatric disorders | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| Depression subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 2 / 33 (6.06%) 2 | 1 / 27 (3.70%) 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 1 / 33 (3.03%) 1 | 1 / 27 (3.70%) 1 |
| Myalgia subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Back pain subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 1 / 33 (3.03%) 1 | 1 / 27 (3.70%) 2 |
| Arthralgia subjects affected / exposed occurrences (all) | 3 / 29 (10.34%) 3 | 0 / 33 (0.00%) 0 | 1 / 27 (3.70%) 1 |
| Infections and infestations | | | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 2 | 3 / 33 (9.09%) 3 | 4 / 27 (14.81%) 4 |
| Influenza subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Ear infection subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 2 / 27 (7.41%) 2 |
| COVID-19 subjects affected / exposed occurrences (all) | 3 / 29 (10.34%) 3 | 8 / 33 (24.24%) 8 | 1 / 27 (3.70%) 1 |
| Bacteriuria subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 1 / 33 (3.03%) 1 | 0 / 27 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 2 / 29 (6.90%) 2 | 3 / 33 (9.09%) 3 | 0 / 27 (0.00%) 0 |
| Upper respiratory tract infection | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 29 (3.45%) 1 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |
| Tonsillitis | | | |
| subjects affected / exposed occurrences (all) | 0 / 29 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 27 (0.00%) 0 |

| Non-serious adverse events | Cohort D-LOU064 25 mg | Cohort D-LOU064 100 mg | Pooled Placebo |
|---|-----------------------|------------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 26 / 33 (78.79%) | 15 / 33 (45.45%) | 33 / 50 (66.00%) |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 2 / 33 (6.06%) | 0 / 33 (0.00%) | 1 / 50 (2.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Bacterial test positive | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 2 / 33 (6.06%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 2 / 33 (6.06%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nitrite urine present | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 0 / 50 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Crystal urine present | | | |
| subjects affected / exposed | 0 / 33 (0.00%) | 1 / 33 (3.03%) | 5 / 50 (10.00%) |
| occurrences (all) | 0 | 1 | 6 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 2 / 33 (6.06%) | 0 / 33 (0.00%) | 3 / 50 (6.00%) |
| occurrences (all) | 2 | 0 | 4 |
| Urine albumin/creatinine ratio increased | | | |
| subjects affected / exposed | 1 / 33 (3.03%) | 1 / 33 (3.03%) | 2 / 50 (4.00%) |
| occurrences (all) | 1 | 1 | 2 |
| Vascular disorders | | | |

| | | | |
|--|----------------------|---------------------|----------------------|
| Hypertension subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 3 | 0 / 33 (0.00%) 0 | 4 / 50 (8.00%) 4 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 4 / 33 (12.12%) 9 | 0 / 33 (0.00%) 0 | 6 / 50 (12.00%) 8 |
| Dizziness subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 1 / 33 (3.03%) 1 | 1 / 50 (2.00%) 1 |
| General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all) | 3 / 33 (9.09%) 3 | 1 / 33 (3.03%) 1 | 4 / 50 (8.00%) 4 |
| Asthenia subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 3 / 50 (6.00%) 3 |
| Pyrexia subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 2 / 50 (4.00%) 2 |
| Blood and lymphatic system disorders Increased tendency to bruise subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 2 / 33 (6.06%) 2 | 0 / 50 (0.00%) 0 |
| Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 3 / 33 (9.09%) 3 | 5 / 50 (10.00%) 5 |
| Constipation subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 2 / 33 (6.06%) 2 | 1 / 50 (2.00%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 2 / 50 (4.00%) 3 |
| Flatulence | | | |

| | | | |
|---|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 1 / 33 (3.03%) 1 | 2 / 50 (4.00%) 2 |
| Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 1 / 33 (3.03%) 1 | 0 / 50 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 1 / 33 (3.03%) 1 | 2 / 50 (4.00%) 2 |
| Pain of skin subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 1 / 33 (3.03%) 1 | 0 / 50 (0.00%) 0 |
| Hidradenitis subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 0 / 33 (0.00%) 0 | 5 / 50 (10.00%) 5 |
| Erythema subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Renal and urinary disorders Proteinuria subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 2 / 50 (4.00%) 2 |
| Psychiatric disorders Depression subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 0 / 33 (0.00%) 0 | 1 / 50 (2.00%) 1 |
| Myalgia | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Back pain subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 0 / 33 (0.00%) 0 | 1 / 50 (2.00%) 1 |
| Arthralgia subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 0 / 33 (0.00%) 0 | 2 / 50 (4.00%) 4 |
| Infections and infestations | | | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 7 / 33 (21.21%) 7 | 2 / 33 (6.06%) 2 | 1 / 50 (2.00%) 1 |
| Influenza subjects affected / exposed occurrences (all) | 1 / 33 (3.03%) 1 | 0 / 33 (0.00%) 0 | 3 / 50 (6.00%) 3 |
| Ear infection subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| COVID-19 subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 2 / 33 (6.06%) 2 | 3 / 50 (6.00%) 3 |
| Bacteriuria subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 0 / 33 (0.00%) 0 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 1 / 33 (3.03%) 2 | 2 / 50 (4.00%) 2 |
| Tonsillitis subjects affected / exposed occurrences (all) | 2 / 33 (6.06%) 2 | 0 / 33 (0.00%) 0 | 0 / 50 (0.00%) 0 |

| | | | |
|---|-------|--|--|
| Non-serious adverse events | Total | | |
| Total subjects affected by non-serious adverse events | | | |

| subjects affected / exposed | 138 / 205 (67.32%) | | |
|--|--------------------|--|--|
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 3 / 205 (1.46%) | | |
| occurrences (all) | 3 | | |
| Bacterial test positive | | | |
| subjects affected / exposed | 4 / 205 (1.95%) | | |
| occurrences (all) | 4 | | |
| Blood glucose increased | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | | |
| occurrences (all) | 2 | | |
| Blood urine present | | | |
| subjects affected / exposed | 5 / 205 (2.44%) | | |
| occurrences (all) | 5 | | |
| Nitrite urine present | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | | |
| occurrences (all) | 3 | | |
| Crystal urine present | | | |
| subjects affected / exposed | 7 / 205 (3.41%) | | |
| occurrences (all) | 8 | | |
| C-reactive protein increased | | | |
| subjects affected / exposed | 7 / 205 (3.41%) | | |
| occurrences (all) | 8 | | |
| Urine albumin/creatinine ratio increased | | | |
| subjects affected / exposed | 10 / 205 (4.88%) | | |
| occurrences (all) | 12 | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 9 / 205 (4.39%) | | |
| occurrences (all) | 10 | | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 21 / 205 (10.24%) | | |
| occurrences (all) | 32 | | |
| Dizziness | | | |

| | | | |
|---|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 7 / 205 (3.41%) 8 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 16 / 205 (7.80%) | | |
| occurrences (all) | 16 | | |
| Asthenia | | | |
| subjects affected / exposed | 10 / 205 (4.88%) | | |
| occurrences (all) | 10 | | |
| Pyrexia | | | |
| subjects affected / exposed | 9 / 205 (4.39%) | | |
| occurrences (all) | 10 | | |
| Blood and lymphatic system disorders | | | |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | | |
| occurrences (all) | 2 | | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 14 / 205 (6.83%) | | |
| occurrences (all) | 14 | | |
| Constipation | | | |
| subjects affected / exposed | 4 / 205 (1.95%) | | |
| occurrences (all) | 4 | | |
| Nausea | | | |
| subjects affected / exposed | 6 / 205 (2.93%) | | |
| occurrences (all) | 7 | | |
| Flatulence | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | | |
| occurrences (all) | 2 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 6 / 205 (2.93%) | | |
| occurrences (all) | 6 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 7 / 205 (3.41%) | | |
| occurrences (all) | 7 | | |

| | | | |
|---|--|--|--|
| <p>Skin and subcutaneous tissue disorders</p> <p>Pruritus</p> <p>subjects affected / exposed</p> <p>6 / 205 (2.93%)</p> <p>occurrences (all)</p> <p>6</p> <p>Pain of skin</p> <p>subjects affected / exposed</p> <p>3 / 205 (1.46%)</p> <p>occurrences (all)</p> <p>3</p> <p>Hidradenitis</p> <p>subjects affected / exposed</p> <p>13 / 205 (6.34%)</p> <p>occurrences (all)</p> <p>15</p> <p>Erythema</p> <p>subjects affected / exposed</p> <p>4 / 205 (1.95%)</p> <p>occurrences (all)</p> <p>4</p> | | | |
| <p>Renal and urinary disorders</p> <p>Proteinuria</p> <p>subjects affected / exposed</p> <p>6 / 205 (2.93%)</p> <p>occurrences (all)</p> <p>6</p> | | | |
| <p>Psychiatric disorders</p> <p>Depression</p> <p>subjects affected / exposed</p> <p>3 / 205 (1.46%)</p> <p>occurrences (all)</p> <p>3</p> | | | |
| <p>Musculoskeletal and connective tissue disorders</p> <p>Pain in extremity</p> <p>subjects affected / exposed</p> <p>6 / 205 (2.93%)</p> <p>occurrences (all)</p> <p>6</p> <p>Myalgia</p> <p>subjects affected / exposed</p> <p>2 / 205 (0.98%)</p> <p>occurrences (all)</p> <p>2</p> <p>Back pain</p> <p>subjects affected / exposed</p> <p>5 / 205 (2.44%)</p> <p>occurrences (all)</p> <p>6</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>7 / 205 (3.41%)</p> <p>occurrences (all)</p> <p>9</p> | | | |
| <p>Infections and infestations</p> | | | |

| | | | |
|-----------------------------------|------------------|--|--|
| Nasopharyngitis | | | |
| subjects affected / exposed | 18 / 205 (8.78%) | | |
| occurrences (all) | 19 | | |
| Influenza | | | |
| subjects affected / exposed | 4 / 205 (1.95%) | | |
| occurrences (all) | 4 | | |
| Ear infection | | | |
| subjects affected / exposed | 4 / 205 (1.95%) | | |
| occurrences (all) | 4 | | |
| COVID-19 | | | |
| subjects affected / exposed | 19 / 205 (9.27%) | | |
| occurrences (all) | 19 | | |
| Bacteriuria | | | |
| subjects affected / exposed | 3 / 205 (1.46%) | | |
| occurrences (all) | 3 | | |
| Sinusitis | | | |
| subjects affected / exposed | 5 / 205 (2.44%) | | |
| occurrences (all) | 5 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 6 / 205 (2.93%) | | |
| occurrences (all) | 7 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | | |
| occurrences (all) | 2 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 24 July 2019 | The main purpose of this amendment was to remove the requirement for male contraception in the LYS006 cohort given that completed preclinical safety studies with LYS006 showed there was no teratogenic or genotoxic potential observed with LYS006 |
| 19 June 2020 | The main purpose of this amendment was to address requests from Health Authorities and Ethics Committees, as well as to correct some inconsistencies in the protocol discovered during implementation. |
| 26 February 2021 | The main purpose of this amendment was to introduce an additional cohort (Cohort C) into this platform study. |
| 03 December 2021 | The main purpose of this amendment was to introduce an additional cohort (Cohort D) into this platform study. |
| 03 February 2022 | The purpose of this amendment was to add a blood sample for coagulation parameters to Cohort D, for safety monitoring reasons. |
| 03 June 2022 | The purpose of this amendment was to address comments raised by the Health Authority. |
| 14 March 2023 | The main purpose of this amendment was to introduce an additional cohort (Cohort E) into this platform study. |
| 12 July 2023 | The main purpose of this amendment was to update the dosage form for Cohort E. |
| 29 November 2023 | The main purpose of this amendment was to revise the exclusion criteria specific to Cohort E. |
| 24 May 2024 | The main purpose of this amendment was to introduce the Auxiliary Medicinal Products (AxMP) definition and related safety reporting rules, to comply with EU Clinical Trial Regulation 536/2014 (EU CTR). |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|-------------|---|-----------------|
| 24 May 2023 | Novartis filed a study Temporary Halt in May 2023 to maintain the study active as Cohort D was about to be completed and the submission of Cohort E-related protocol amendment (Amendment No. 8) was in process of preparation. | 09 January 2024 |

Notes:

Limitations and caveats

None reported